What is the current size and annual growth rate of the breast cancer monoclonal antibodies market?
The breast cancer monoclonal antibodies market size has grown strongly in recent years. It will grow from $18.97 billion in 2024 to $20.18 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the rising prevalence of breast cancer, increasing awareness of breast cancer monoclonal antibodies, growing clinical efficacy, and patient demand.
The breast cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $27.8 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to emerging targets, biosimilars, combination therapies, global incidence and aging population, and personalized medicine. Major trends in the forecast period include advances in early breast cancer detection, immunotherapy integration, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, and long-term survivorship support.
Get Your Free Sample of The Global Breast Cancer Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3450&type=smp
Which major factors have contributed to the expansion of the breast cancer monoclonal antibodies market?
Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibody market’s growth. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of breast cancer cases increased from 284,200 in 2021 to 300,590 in 2023, reflecting a growth of 5.76%. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibody market.
How is the breast cancer monoclonal antibodies market segmented?
The breast cancer monoclonal antibodies market covered in this report is segmented –
1) By Product: Naked Mabs, Conjugated Mabs
2) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy
3) By End-User: Hospitals, Retail Pharmacies
Subsegments:
1) By Naked MABs: Trastuzumab (Herceptin), Rituximab, Cetuximab, Other Naked MABs
2) By Conjugated MABs: Ado-trastuzumab emtansine (Kadcyla), Brentuximab vedotin, Other Conjugated MABs
Order your report now for swift delivery
Who are the top competitors in the breast cancer monoclonal antibodies market?
Major companies operating in the breast cancer monoclonal antibodies market include Amgen Inc., Mylan N.V., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc., Daiichi Sankyo Company Ltd., Biocad, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celldex Therapeutics Inc., Celltrion Inc., F. Hoffmann-La Roche AG, Immunomedics Inc., MacroGenics Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Puma Biotechnology Inc., Seattle Genetics Inc., AstraZeneca plc, Eddingpharm, Eisai Co. Ltd., ImmunoGen Inc., Eli Lilly and Company, AbbVie Inc., Johnson & Johnson, Mersana Therapeutics Inc., Immunocore Limited, Immunovative Therapies Ltd.
How will evolving trends contribute to the growth of the breast cancer monoclonal antibodies market?
Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccines. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.
What are the major regional insights for the breast cancer monoclonal antibodies market, and which region holds the top position?
North America was the largest region in the breast cancer monoclonal antibodies market in 2024. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Breast Cancer Monoclonal Antibodies Market Report 2025 Offer?
The breast cancer monoclonal antibodies market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Breast cancer monoclonal antibodies (mABs) refer to the use of antibodies in the treatment of both early-stage and advanced breast cancer. It functions by identifying and locating particular proteins in cancer cells. Every MAB recognizes a different protein. Therefore, different MABs must be created to target various cancer types. They kill the cancer cell in various ways depending on the protein they are targeting.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3450
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
